Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

BACKGROUND: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are also immunosuppressants and are used clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y, Wang, X-Y, Subjeck, J R, Shrikant, P A, Kim, H L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049595/
https://www.ncbi.nlm.nih.gov/pubmed/21285988
http://dx.doi.org/10.1038/bjc.2011.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049595/
https://www.ncbi.nlm.nih.gov/pubmed/21285988
http://dx.doi.org/10.1038/bjc.2011.15

Ejemplares similares